Raymond James Believes Antares Pharma (ATRS) Still Has Room to Grow
In a report released today, Elliot Wilbur from Raymond James maintained a Buy rating on Antares Pharma (ATRS). The company’s shares closed last Monday at $4.78, close to its 52-week high of $5.07.
According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -0.5% and a 47.4% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Antares Pharma with a $6.00 average price target, a 25.8% upside from current levels. In a report issued on February 10, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
Antares Pharma’s market cap is currently $805M and has a P/E ratio of 80.80. The company has a Price to Book ratio of 12.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.